Global Avascular Necrosis Market Research Report – Forecast to 2024

Table of Contents

Table of Contents: 1 Executive Summary 2 Market Introduction 2.1 Scope of Study 2.2 Research Objective 2.3 List of Assumptions 2.4 Market Structure 3 Research Methodology 3.1 Research Process 3.2 Primary Research 3.3 Secondary Research 3.4 Market Size Estimation 3.5 Forecast Model 4 Market Dynamics 4.1 Introduction 4.2 Drivers 4.2.1 Increasing awareness along with the high prevalence of the avascular necrosis disease 4.2.2 Rising preference of surgeries to cure osteonecrosis 4.2.3 Rising preference of bone grafting surgical procedures with the less pain substitute procedures 4.2.4 Consolidation of large healthcare providers in the U.S. 4.2.5 Technological advancements in the development of surgical implants 4.3 Restraints 4.3.1 The high cost of surgical procedures and related side effects 4.3.2 Worsening regulatory landscape and growing cost of noncompliance in developed countries 4.4 Opportunities 4.4.1 Growing demand for non-invasive treatments for faster recovery 4.5 Technology Trends & Assessment 4.5.1 Acceptance of synthetic bone-graft over natural ones 4.5.2 Nanotechnology 4.5.3 Rising demand for incorporating recombinant DNA technology in surgical implants 4.5.4 Development of titanium-foam implant for bone grafting 4.5.5 Customized Degradable Implants 5 Market Factor Analysis 5.1 Porter’s Five Forces Model 5.1.1 Bargaining Power of Suppliers 5.1.2 Bargaining Power of Buyers 5.1.3 Threat of New Entrants 5.1.4 Threat of Substitutes 5.1.5 Intensity of Rivalry 5.2 Value Chain Analysis 5.2.1 Research & Development 5.2.2 Manufacturing 5.2.3 Distribution 5.2.4 Marketing & Sales 5.2.5 Post-Sales Monitoring 5.3 Epidemiology of Avascular Necrosis 6 Global Avascular Necrosis Market, by Type 6.1 Introduction 6.2 Non-trauma Related Avascular Necrosis 6.2.1 Age Group 6.2.1.1 Third Decade 6.2.1.2 Fifth Decade 6.2.2 Causes 6.2.2.1 Caisson disease 6.2.2.2 Sickle cell anaemia 6.2.2.3 Steroid Abuse 6.2.2.4 Alcohol Abuse 6.3 Trauma-Related Avascular Necrosis 7 Global Avascular Necrosis Market, by Site 7.1 Introduction 7.2 Hip Bone 7.3 Knee 7.4 Shoulder 8 Global Avascular Necrosis Market, by Diagnosis 8.1 Introduction 8.2 Imaging 8.2.1 X-Ray 8.2.2 CT Scan 8.2.3 MRI 8.2.4 PET 8.3 Biopsy 9 Global Avascular Necrosis Market, by Treatment 9.1 Introduction 9.2 Medication 9.2.1 Medication by NSAIDs (Non-Steroidal Anti-inflammatory Drugs) 9.2.2 Medication by Bisphosphonates 9.2.3 Medication by Blood Thinners 9.3 Electrical Stimulation 9.4 Gene Therapy 9.5 Surgery 9.5.1 Core Decompression 9.5.2 Osteotomy 9.5.3 Bone Graft 9.5.4 Arthoplasty 10 Global Avascular Necrosis Market, by End-User 10.1 Introduction 10.2 Hospitals & Clinics 10.3 Diagnostic Centers 10.4 Ambulatory Surgical Centers 11 Global Avascular Necrosis Market, by Region 11.1 Introduction 11.2 Americas 11.2.1 North America 11.2.1.1 U.S. 11.2.1.2 Canada 11.2.2 South America 11.3 Europe 11.3.1 Western Europe 11.3.1.1 Germany 11.3.1.2 France 11.3.1.3 UK 11.3.1.4 Italy 11.3.1.5 Spain 11.3.1.6 Rest of Western Europe 11.3.2 Eastern Europe 11.4 Asia Pacific 11.4.1 Japan 11.4.2 China 11.4.3 India 11.4.4 Australia 11.4.5 Republic of Korea 11.4.6 Rest of Asia Pacific 11.5 The Middle East & Africa 11.5.1.1 The Middle East 11.5.1.2 Africa 12 Competitive Landscape 12.1 Introduction 12.2 Company Market Share Analysis 12.2.1 Introduction 12.3 Key Developments 13 Company Profiles 13.1 Sanofi 13.1.1 Company Overview 13.1.2 Financial Overview 13.1.3 Products Offering 13.1.4 Key Developments 13.1.5 SWOT Analysis 13.1.6 Key Strategy 13.2 Bayer Healthcare AG 13.2.1 Company Overview 13.2.2 Financial Overview 13.2.3 Products Offering 13.2.4 Key Developments 13.2.5 SWOT Analysis 13.2.6 Key Strategy 13.3 Boehringer Ingelheim GmbH 13.3.1 Company Overview 13.3.2 Financial Overview 13.3.3 Products Offering 13.3.4 Key Developments 13.3.5 SWOT Analysis 13.3.6 Key Strategy 13.4 Pfizer Inc. 13.4.1 Company Overview 13.4.2 Financial Overview 13.4.3 Products Offering 13.4.4 Key Developments 13.4.5 SWOT Analysis 13.4.6 Key Strategy 13.5 Merck KGaA 13.5.1 Company Overview 13.5.2 Financial Overview 13.5.3 Products Offering 13.5.4 Key Developments 13.5.5 SWOT Analysis 13.5.6 Key Strategy 13.6 Stryker Corporation 13.6.1 Company Overview 13.6.2 Financial Overview 13.6.3 Products Offering 13.6.4 Key Developments 13.6.5 SWOT Analysis 13.6.6 Key Strategy 13.7 Medtronic PLC 13.7.1 Company Overview 13.7.2 Financial Overview 13.7.3 Products Offering 13.7.4 Key Developments 13.7.5 SWOT Analysis 13.7.6 Key Strategy 13.8 Aurobindo Pharma 13.8.1 Company Overview 13.8.2 Financial Overview 13.8.3 Products Offering 13.8.4 Key Developments 13.8.5 SWOT Analysis 13.8.6 Key Strategy 13.9 Integra LifeSciences Corporation 13.9.1 Company Overview 13.9.2 Financial Overview 13.9.3 Products Offering 13.9.4 Key Developments 13.9.5 SWOT Analysis 13.9.6 Key Strategy 13.1 Zimmer Biomet Holdings 13.10.1 Company Overview 13.10.2 Financial Overview 13.10.3 Products Offering 13.10.4 Key Developments 13.10.5 SWOT Analysis 13.10.6 Key Strategy 13.11 Wright Medical Group N.V. 13.11.1 Company Overview 13.11.2 Financial Overview 13.11.3 Products Offering 13.11.4 Key Developments 13.11.5 SWOT Analysis 13.11.6 Key Strategy 13.12 Grifols SA 13.12.1 Company Overview 13.12.2 Financial Overview 13.12.3 Products Offering 13.12.4 Key Developments 13.12.5 SWOT Analysis 13.12.6 Key Strategy 13.13 Smith & Nephew 13.13.1 Company Overview 13.13.2 Financial Overview 13.13.3 Products Offering 13.13.4 Key Developments 13.13.5 SWOT Analysis 13.13.6 Key Strategy 13.14 Ethicon Inc. 13.14.1 Company Overview 13.14.2 Financial Overview 13.14.3 Products Offering 13.14.4 Key Developments 13.14.5 SWOT Analysis 13.14.6 Key Strategy 14 Conclusion 14.1 Key Findings 14.1.1 CEO’s Viewpoint 14.1.2 Unmet Needs 14.1.3 Key Companies to Watch 14.1.4 Prediction 15 Appendix 15.1 Discussion Blue Print